So, LINC02432/hsa-miR-98–5p/HK2 axis was therefore suggested as an auxiliary marker for SIGLEC15 blocking immunotherapy, and as a potential therapeutic target for PAAD. The gene discussed is SIGLEC15; the disease is pancreatic adenocarcinoma.